Hypertension is the leading risk factor for death and disability worldwide and a major contributor to premature mortality. Individuals with hypertension often exhibit alterations in lipid and glucose metabolism, further increasing their risk of severe cardiovascular complications. The present study evaluated the lipid profile and blood sugar among hypertensive individuals in Yenagoa, Nigeria. A total of 246 subjects (31-60 years) were recruited for the study. They consisted of 172 hypertensives attending the Cardiology Clinic of Niger Delta University Teaching Hospital (NDUTH) and 74 normotensive control subjects drawn from the staff of NDUTH. Body mass index, fasting blood sugar and lipid profile were measured following standard protocols. The result of this study shows a significantly elevated mean levels of fasting blood sugar (FBS), total cholesterol (TC), triglycerides (TG), and low-density lipoproteins (LDL) among hypertensive subjects compared to the normotensive controls (p<0.05). Fasting blood sugar showed sex and age-dependent variations among the hypertensives. Male hypertensive subjects had a significantly higher fasting blood sugar compared to the female hypertensives (p<0.05). Also, fasting blood sugar increased with age for both hypertensive and normotensive subjects regardless of gender. The current evidence has identified elevated BMI, FBS, TC, TG, and LDL among hypertensive patients receiving medical care at a tertiary healthcare facility in Yenagoa, Nigeria. These findings underscore the significant association between hypertension and metabolic risk factors and recommend routine assessments of these metabolic parameters among hypertensive patients.
Published in | International Journal of Clinical and Experimental Medical Sciences (Volume 11, Issue 1) |
DOI | 10.11648/j.ijcems.20251101.11 |
Page(s) | 1-10 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2025. Published by Science Publishing Group |
Hypertension, Body Mass Index, Lipid Profile, Fasting Blood Sugar, Cardiovascular Risk
Parameters | Normotensive n=74 | Hypertensive n=172 | T-test p-value |
---|---|---|---|
Age (Yrs) | 45.15±8.08 | 45.97±6.71 | 0.412 |
Body mass index (kg/m2) | 25.27±5.08 | 28.66±5.54* | 0.001 |
Systolic blood pressure (mmHg) | 113.27±9.65 | 133.84±22.15* | 0.001 |
Diastolic blood pressure (mmHg) | 74.92±8.24 | 83.46±14.65* | 0.001 |
Mean arterial pressure (mmHg) | 86.42±8.14 | 98.57±16.18* | 0.001 |
Parameters | Normotensive n=74 | Hypertensive n=172 | T-test p-value |
---|---|---|---|
Fasting blood sugar (mg/dL) | 91.80±17.83 | 113.17±25.14* | 0.01 |
Total cholesterol (mmol/L) | 5.15±1.46 | 6.14±2.09* | 0.01 |
Triglycerides (mmol/L) | 1.23±0.75 | 1.44±0.79* | 0.04 |
High-density lipoproteins (mmol/L) | 1.61±0.38 | 1.83±0.7 | 0.06 |
Low-density lipoproteins (mmol/L) | 3.02±1.33 | 3.67±2.0* | 0.01 |
Male | Female | |||
---|---|---|---|---|
Parameters | Normotensive (n=31) | Hypertensive (n=69) | Normotensive (n=43) | Hypertensive (n=103) |
FBS (mg/dL) | 86.39±12.81 | 122.59±28.12* | 95.70±19.96 | 106.85±20.78* |
TC (mmol/L) | 5.24±1.44 | 5.03±1.87 | 5.09±1.48 | 6.89±1.89* |
TG (mmol/L) | 1.32±0.89 | 1.30±0.95 | 1.17±0.63 | 1.54±0.65* |
HDL (mmol/L) | 1.47±0.26 | 1.58±0.60 | 1.71±0.42 | 2.00±0.66* |
LDL (mmol/L) | 3.17±1.03 | 2.86±1.71 | 2.92±1.52 | 4.22±2.01* |
Age (years) | Participants | FBS (mg/dL) | TC (mmol/L) | TG (mmol/L) | HDL (mmol/L) | LDL (mmol/L) |
---|---|---|---|---|---|---|
31 – 40 | Normotensive (n=31) | 78.81±13.20 | 5.63±0.77 | 1.07±0.49 | 1.59±0.32 | 3.55±0.6 |
Hypertensive (n=38) | 105.32±24.53* | 6.85±2.02* | 1.37±0.46* | 1.98±0.71 | 4.26±1.89* | |
41 – 50 | Normotensive (n=31) | 94.21±12.80 | 5.29±1.64 | 1.25±1.03 | 1.56±0.37 | 3.16±1.12 |
Hypertensive (n=74) | 111.96±22.13* | 5.62±2.00* | 1.49±0.81* | 1.81±0.66 | 3.17±1.97 | |
51 – 60 | Normotensive (n=24) | 106.67±13.81 | 4.42±1.72 | 1.42±0.75 | 1.68±0.45 | 2.23±1.77 |
Hypertensive (n=60) | 113.17±25.14* | 6.34±2.11* | 1.43±0.93 | 1.77±0.66 | 3.93±1.98* |
NDUTH | Niger Delta University Teaching Hospital |
FBS | Fasting Blood Sugar |
TC | Total Cholesterol |
TG | Triglycerides |
LDL | Low-density Lipoprotein |
HDL | High-density Lipoprotein |
BMI | Body Mass Index |
CVD | Cardiovascular Diseases |
WMA | World Medical Association |
ANOVA | Analysis of Variance |
NO | Nitric Oxide |
TNF-α | Tumour Necrotic Factor α |
IL-6 | Interleukin 6 |
ox-LDL | Oxidized Low-Density Lipoprotein |
RAAS | Renin Agiontensin Aldosterone System |
AGE | Advanced Glycation End Product |
[1] | Sliwa K, Stewart S, Gersh BJ. Hypertension: a global perspective. Circulation. 2011; 123(24): 2892-6. |
[2] | Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Annals of internal medicine. 2003; 139(9): 761-76. |
[3] | Ibrahim MM, Damasceno A. Hypertension in developing countries. The Lancet. 2012; 380(9841): 611-9. |
[4] | Erho SA, Chinko BC, Aduema W, Fente EA. Patterns of Iron Biomarkers among Hypertensive Individuals in Yenagoa, Bayelsa State, Nigeria. Asian Journal of Medicine and Health. 2024; 22: 94-103. |
[5] | Bovet P, Schutte AE, Banatvala N, Burnier M. Hypertension: burden, epidemiology and priority interventions. Noncommunicable diseases: Routledge; 2023: 58-65. |
[6] | World Health Organization. Global report on hypertension: the race against a silent killer: World Health Organization; 2023. |
[7] | Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015–2016. NCHS Data Brief. 2017(288): 1-8. |
[8] | Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nature Reviews Nephrology. 2020; 16(4): 223-37. |
[9] | Elliott WJ. The Economic Impact of Hypertension. The Journal of Clinical Hypertension. 2003; 5(3): 3-13. |
[10] | Spence JD. Hypertension in Africa. SAGE Publications Sage UK: London, England; 2019: 455-7. |
[11] | Adeloye D, Basquill C. Estimating the prevalence and awareness rates of hypertension in Africa: a systematic analysis. PloS one. 2014; 9(8): e104300. |
[12] | Adeloye D, Basquill C, Aderemi AV, Thompson JY, Obi FA. An estimate of the prevalence of hypertension in Nigeria: a systematic review and meta-analysis. Journal of hypertension. 2015; 33(2): 230-42. |
[13] | Adeke AS, Chori BS, Neupane D, Sharman JE, Odili AN. Socio-demographic and lifestyle factors associated with hypertension in Nigeria: results from a country-wide survey. Journal of human hypertension. 2024; 38(4): 365-70. |
[14] | Ezeala-Adikaibe BA, Mbadiwe CN, Okafor UH, Nwobodo UM, Okwara CC, Okoli CP, et al. Prevalence of hypertension in a rural community in southeastern Nigeria; an opportunity for early intervention. Journal of Human Hypertension. 2023; 37(8): 694-700. |
[15] | Odili AN, Chori BS, Danladi B, Nwakile PC, Okoye IC, Abdullahi U, et al. Prevalence, awareness, treatment and control of hypertension in Nigeria: data from a nationwide survey 2017. Global heart. 2020; 15(1): 47. |
[16] | Beevers G, Lip GY, O'Brien E. ABC of hypertension: The pathophysiology of hypertension. Bmj. 2001; 322(7291): 912-6. |
[17] | Charles L, Triscott J, Dobbs B. Secondary hypertension: discovering the underlying cause. American family physician. 2017; 96(7): 453-61. |
[18] | Chruściel P, Stemplewska P, Stemplewski A, Wattad M, Bielecka-Dąbrowa A, Maciejewski M, et al. Associations between the lipid profile and the development of hypertension in young individuals–the preliminary study. Archives of Medical Science: AMS. 2019; 18(1): 25. |
[19] | Poorolajal J, Farbakhsh F, Mahjub H, Bidarafsh A, Babaee E. How much excess body weight, blood sugar, or age can double the risk of hypertension? Public health. 2016; 133: 14-8. |
[20] | Chen S, Cheng W. Relationship between lipid profiles and hypertension: a cross-sectional study of 62,957 Chinese adult males. Frontiers in public health. 2022; 10: 895499. |
[21] | Borade A, Kadam G, Bhide G, Dhongade R. Study of blood pressure and blood sugar levels in adolescence and comparison with body mass index. Indian journal of medical sciences. 2011; 65(7): 297. |
[22] | Nwafor A, Mmom FC, Obia O, Obiandu C, Hart VO, Chinko BC. Relationship between blood pressure, blood glucose and body mass index and coexisting prehypertension and prediabetes among rural adults in Niger Delta Region, Nigeria. British Journal of Medicine & Medical Research. 2015; 9(7): 1-12. |
[23] | Eziuzo CI, Chinko BC, Dapper DV. Comparative assessment of some white blood cell and platelet parameters among normotensive and hypertensive subjects in Port Harcourt, Nigeria. Nigerian Medical Journal. 2017; 58(4): 131-7. |
[24] | Bozkurt B, Aguilar D, Deswal A, Dunbar SB, Francis GS, Horwich T, et al. Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association. Circulation. 2016; 134(23): e535-e78. |
[25] | Gorial FI, Hameed JRA, Yassen NS. Relationship between serum lipid profile and hypertension. Journal of the Faculty of Medicine Baghdad. 2012; 54(2): 134-7. |
[26] | World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human participants. JAMA. 2025; 333(1): 71-4. |
[27] | Colin Bell A, Adair LS, Popkin BM. Ethnic Differences in the Association between Body Mass Index and Hypertension. American Journal of Epidemiology. 2002; 155(4): 346-53. |
[28] | Valensi P. Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications. Cardiovascular diabetology. 2021; 20(1): 170. |
[29] | Park M, Jung SJ, Yoon S, Yun JM, Yoon H-J. Association between the markers of metabolic acid load and higher all-cause and cardiovascular mortality in a general population with preserved renal function. Hypertension Research. 2015; 38(6): 433-8. |
[30] | Hall JE, da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S, et al. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. Journal of Biological Chemistry. 2010; 285(23): 17271-6. |
[31] | Lobato NdS, Filgueira FP, Akamine EH, Tostes R, Carvalho MHCd, Fortes ZB. Mechanisms of endothelial dysfunction in obesity-associated hypertension. Brazilian journal of medical and biological research. 2012; 45: 392-400. |
[32] | Engin A. Endothelial dysfunction in obesity. Adv Exp Med Biol. 2017; 960: 345-79. |
[33] | Granger JP. An emerging role for inflammatory cytokines in hypertension. American Journal of Physiology-Heart and Circulatory Physiology. 2006; 290(3): H923-H4. |
[34] | Egbi OG, Rotifa S, Jumbo J. Prevalence of hypertension and its correlates among employees of a tertiary hospital in Yenagoa, Nigeria. Annals of African medicine. 2015; 14(1): 8-17. |
[35] | Prince AEL, George MD, Dorcas A-GD. Body mass index of Hypertensive and non Hypertensive Residents in a Semi-urban area of Bayelsa, Nigeria. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS). 2013; 12(5): 19-22. |
[36] | Uvoh S, Asara A, Chinko B, Goodhope B. Correlation of Serum Cholesterol, Electrolytes, and Body Mass Index With Cardiovascular Status of Selected Adults in Bayelsa State Nigeria. European Journal of Pharmaceutical and Medical Research. 2017; 4(7): 110-7. |
[37] | Kreisberg RA, Oberman A. Medical management of hyperlipidemia/dyslipidemia. The Journal of Clinical Endocrinology & Metabolism. 2003; 88(6): 2445-61. |
[38] | Walsh T, Donnelly T, Lyons D. Impaired endothelial nitric oxide bioavailability: a common link between aging, hypertension, and atherogenesis? Journal of the American Geriatrics Society. 2009; 57(1): 140-5. |
[39] | Hermann M, Flammer A, Lüscher TF. Nitric oxide in hypertension. The Journal of Clinical Hypertension. 2006; 8: 17-29. |
[40] | Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004; 109(23_suppl_1): III-27-III-32. |
[41] | Shimokawa H. Primary endothelial dysfunction: atherosclerosis. Journal of molecular and cellular cardiology. 1999; 31(1): 23-37. |
[42] | Nickenig G, Harrison DG. The AT1-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation. 2002; 105(3): 393-6. |
[43] | Skultetyova D, Filipova S, Riecansky I, Skultety J. The role of angiotensin type 1 receptor in inflammation and endothelial dysfunction. Recent Patents on Cardiovascular Drug Discovery (Discontinued). 2007; 2(1): 23-7. |
[44] | Minh HV, Tien HA, Sinh CT, Thang DC, Chen CH, Tay JC, et al. Assessment of preferred methods to measure insulin resistance in Asian patients with hypertension. The Journal of Clinical Hypertension. 2021; 23(3): 529-37. |
[45] | Brosolo G, Da Porto A, Bulfone L, Vacca A, Bertin N, Scandolin L, et al. Insulin resistance and high blood pressure: mechanistic insight on the role of the kidney. Biomedicines. 2022; 10(10): 2374. |
[46] | Kowara M, Cudnoch-Jedrzejewska A. Different approaches in therapy aiming to stabilize an unstable atherosclerotic plaque. International Journal of Molecular Sciences. 2021; 22(9): 4354. |
[47] | Ifenkwe JC, Udogidi OE, Ononuju U, Gospel A. Lipid Profiles of Urban and Rural Dwellers in Bayelsa State, Nigeria. International Journal of Scientific Research and Engineering Development. 2022; 5(5): 785-96. |
[48] | Ambakederemo TE, Imananagha-Amene BE, Ebuenyi ID. Atherogenic index and relationship with age, gender, and anthropometric measurements among hypertensive patients attending Niger Delta Teaching Hospital. Tropical Journal of Health Sciences. 2016; 23(2): 11-7. |
[49] | Jasper U. Magnitude of obesity, abdominal adiposity and their association with hypertension and diabetes-A cross sectional study. Journal of metabolic syndrome. 2014; 3(146): |
[50] | Abonyi MC, Young EE, Nwatu CB, Ugwueze CV, Nkpozi MO, Okechukwu UC, et al. Insulin resistance and hypertension among type 2 diabetes subjects in a tertiary institution in South East Nigeria. Nigerian Journal of Medicine. 2023; 32(4): 422-7. |
[51] | Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. European heart journal. 2013; 34(31): 2436-43. |
[52] | Furie K, Inzucchi SE. Diabetes mellitus, insulin resistance, hyperglycemia, and stroke. Current neurology and neuroscience reports. 2008; 8: 12-9. |
[53] | Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. American Journal of Hypertension. 2004; 17(S2): 16S-20S. |
[54] | Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nature reviews endocrinology. 2014; 10(5): 293-302. |
[55] | Nesto RW. The relation of insulin resistance syndromes to risk of cardiovascular disease. Reviews in cardiovascular medicine. 2003; 4: S11-8. |
[56] | Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends in immunology. 2004; 25(1): 4-7. |
[57] | Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006; 114(6): 597-605. |
[58] | Singh S, Siva BV, Ravichandiran V. Advanced Glycation End Products: key player of the pathogenesis of atherosclerosis. Glycoconjugate journal. 2022; 39(4): 547-63. |
[59] | McNulty M, Mahmud A, Feely J. Advanced glycation end-products and arterial stiffness in hypertension. American journal of hypertension. 2007; 20(3): 242-7. |
[60] | Mauvais-Jarvis F. Gender differences in glucose homeostasis and diabetes. Physiology & behavior. 2018; 187: 20-3. |
[61] | Mauvais-Jarvis F, Manson JE, Stevenson JC, Fonseca VA. Menopausal hormone therapy and type 2 diabetes prevention: evidence, mechanisms, and clinical implications. Endocrine reviews. 2017; 38(3): 173-88. |
[62] | van Genugten RE, Utzschneider KM, Tong J, Gerchman F, Zraika S, Udayasankar J, et al. Effects of sex and hormone replacement therapy use on the prevalence of isolated impaired fasting glucose and isolated impaired glucose tolerance in subjects with a family history of type 2 diabetes. Diabetes. 2006; 55(12): 3529-35. |
[63] | Nuutila P, Knuuti MJ, Mäki M, Laine H, Ruotsalainen U, Teräs M, et al. Gender and insulin sensitivity in the heart and in skeletal muscles: studies using positron emission tomography. Diabetes. 1995; 44(1): 31-6. |
[64] | Blüher M, Mantzoros CS. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism. 2015; 64(1): 131-45. |
[65] | Couet C, Delarue J, Constans T, Lamisse F. Age-Related Insulin Resistance; A Review. Hormone Research in Paediatrics. 1992; 38(1-2): 46-50. |
[66] | Rizvi AA, Rizzo M. Age-Related Changes in Insulin Resistance and Muscle Mass: Clinical Implications in Obese Older Adults. Medicina. 2024; 60(10): 1648. |
[67] | Chang AM, Halter JB. Aging and insulin secretion. American Journal of Physiology-Endocrinology and Metabolism. 2003; 284(1): E7-E12. |
[68] | Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu C-Y, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007; 116(1): 39-48. |
[69] | Abraham TM, Pedley A, Massaro JM, Hoffmann U, Fox CS. Association between visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors. Circulation. 2015; 132(17): 1639-47. |
[70] | Park SW, Goodpaster BH, Strotmeyer ES, de Rekeneire N, Harris TB, Schwartz AV, et al. Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes. 2006; 55(6): 1813-8. |
[71] | Park SW, Goodpaster BH, Strotmeyer ES, Kuller LH, Broudeau R, Kammerer C, et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes care. 2007; 30(6): 1507-12. |
[72] | Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences. 2014; 69(Suppl_1): S4-S9. |
[73] | Franceschi C, Zaikin A, Gordleeva S, Ivanchenko M, Bonifazi F, Storci G, Bonafè M. Inflammaging 2018: an update and a model. Seminars in immunology, 2018. 1-5. |
APA Style
Erho, S. A., Aduema, W., Erighanyoyefa, A., Bunu, M. E., Poripo, B. E., et al. (2025). Lipid Profile and Blood Sugar Variations Among Hypertensive Subjects in Yenagoa, Nigeria. International Journal of Clinical and Experimental Medical Sciences, 11(1), 1-10. https://doi.org/10.11648/j.ijcems.20251101.11
ACS Style
Erho, S. A.; Aduema, W.; Erighanyoyefa, A.; Bunu, M. E.; Poripo, B. E., et al. Lipid Profile and Blood Sugar Variations Among Hypertensive Subjects in Yenagoa, Nigeria. Int. J. Clin. Exp. Med. Sci. 2025, 11(1), 1-10. doi: 10.11648/j.ijcems.20251101.11
@article{10.11648/j.ijcems.20251101.11, author = {Simon Akpomemera Erho and Wadioni Aduema and Allen Erighanyoyefa and Mao Ebimobotei Bunu and Blessing Elohor Poripo and Ugorji Nnaemeka Ogbonna and Chimburuoma Nath-Abraham and Bruno Chukwuemeka Chinko}, title = {Lipid Profile and Blood Sugar Variations Among Hypertensive Subjects in Yenagoa, Nigeria }, journal = {International Journal of Clinical and Experimental Medical Sciences}, volume = {11}, number = {1}, pages = {1-10}, doi = {10.11648/j.ijcems.20251101.11}, url = {https://doi.org/10.11648/j.ijcems.20251101.11}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcems.20251101.11}, abstract = {Hypertension is the leading risk factor for death and disability worldwide and a major contributor to premature mortality. Individuals with hypertension often exhibit alterations in lipid and glucose metabolism, further increasing their risk of severe cardiovascular complications. The present study evaluated the lipid profile and blood sugar among hypertensive individuals in Yenagoa, Nigeria. A total of 246 subjects (31-60 years) were recruited for the study. They consisted of 172 hypertensives attending the Cardiology Clinic of Niger Delta University Teaching Hospital (NDUTH) and 74 normotensive control subjects drawn from the staff of NDUTH. Body mass index, fasting blood sugar and lipid profile were measured following standard protocols. The result of this study shows a significantly elevated mean levels of fasting blood sugar (FBS), total cholesterol (TC), triglycerides (TG), and low-density lipoproteins (LDL) among hypertensive subjects compared to the normotensive controls (p<0.05). Fasting blood sugar showed sex and age-dependent variations among the hypertensives. Male hypertensive subjects had a significantly higher fasting blood sugar compared to the female hypertensives (p<0.05). Also, fasting blood sugar increased with age for both hypertensive and normotensive subjects regardless of gender. The current evidence has identified elevated BMI, FBS, TC, TG, and LDL among hypertensive patients receiving medical care at a tertiary healthcare facility in Yenagoa, Nigeria. These findings underscore the significant association between hypertension and metabolic risk factors and recommend routine assessments of these metabolic parameters among hypertensive patients. }, year = {2025} }
TY - JOUR T1 - Lipid Profile and Blood Sugar Variations Among Hypertensive Subjects in Yenagoa, Nigeria AU - Simon Akpomemera Erho AU - Wadioni Aduema AU - Allen Erighanyoyefa AU - Mao Ebimobotei Bunu AU - Blessing Elohor Poripo AU - Ugorji Nnaemeka Ogbonna AU - Chimburuoma Nath-Abraham AU - Bruno Chukwuemeka Chinko Y1 - 2025/03/31 PY - 2025 N1 - https://doi.org/10.11648/j.ijcems.20251101.11 DO - 10.11648/j.ijcems.20251101.11 T2 - International Journal of Clinical and Experimental Medical Sciences JF - International Journal of Clinical and Experimental Medical Sciences JO - International Journal of Clinical and Experimental Medical Sciences SP - 1 EP - 10 PB - Science Publishing Group SN - 2469-8032 UR - https://doi.org/10.11648/j.ijcems.20251101.11 AB - Hypertension is the leading risk factor for death and disability worldwide and a major contributor to premature mortality. Individuals with hypertension often exhibit alterations in lipid and glucose metabolism, further increasing their risk of severe cardiovascular complications. The present study evaluated the lipid profile and blood sugar among hypertensive individuals in Yenagoa, Nigeria. A total of 246 subjects (31-60 years) were recruited for the study. They consisted of 172 hypertensives attending the Cardiology Clinic of Niger Delta University Teaching Hospital (NDUTH) and 74 normotensive control subjects drawn from the staff of NDUTH. Body mass index, fasting blood sugar and lipid profile were measured following standard protocols. The result of this study shows a significantly elevated mean levels of fasting blood sugar (FBS), total cholesterol (TC), triglycerides (TG), and low-density lipoproteins (LDL) among hypertensive subjects compared to the normotensive controls (p<0.05). Fasting blood sugar showed sex and age-dependent variations among the hypertensives. Male hypertensive subjects had a significantly higher fasting blood sugar compared to the female hypertensives (p<0.05). Also, fasting blood sugar increased with age for both hypertensive and normotensive subjects regardless of gender. The current evidence has identified elevated BMI, FBS, TC, TG, and LDL among hypertensive patients receiving medical care at a tertiary healthcare facility in Yenagoa, Nigeria. These findings underscore the significant association between hypertension and metabolic risk factors and recommend routine assessments of these metabolic parameters among hypertensive patients. VL - 11 IS - 1 ER -